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Background: [18F]fluciclatide, a peptide ligand with high affinity for αvβ3/αvβ5 integrins, is a proposed biomarker
of tumor angiogenesis. The study rationale was to perform a preliminary evaluation of the relationship between
tumor [18F]fluciclatide uptake and perfusion by [15O]H2O PET.
Methods: Patients with non-small cell lung cancer and melanoma underwent dynamic imaging with arterial sampling
following injection of [15O]H2O and [
18F]fluciclatide. Quantification was performed using a one-tissue compartmental
model for [15O]H2O and a two-tissue model for [
18F]fluciclatide at volume-of-interest level, and SUV at voxel level.
Results: Tumor binding potential (k3/k4 ratio) of [
18F]fluciclatide tumor was 5.39 ± 1.46, consistent with previous studies
in breast cancer metastases. Voxel-by-voxel maps of [18F]fluciclatide delivery strongly correlated with [15O]H2O-based
perfusion (p < 10−4 tumor, 1,794 ± 1,331 voxels). Interestingly, this correlation was lost when retention of [18F]fluciclatide
at late time-points was compared with perfusion (p > 0.15).
Conclusions: Our study suggests tumor [18F]fluciclatide retention is unrelated to tumor perfusion, supporting use of
late (60-min) imaging protocols in patients.
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Tumor angiogenesis is essential for cancer survival [1].
Many novel therapeutics have been developed which aim
to target this process by acting as either angiogenesis in-
hibitors (e.g. by blocking the action of vascular endothelial
growth factor) or as vascular disrupting agents, which
target the extracellular matrix [2,3]. Despite the recent
advances in therapeutics, there remains a paucity of ef-
fective biomarkers which can predict the response of tu-
mors in vivo to these treatments. One area of promise is
the development of imaging agents that target the αvβ3
and αvβ5 integrins - a set of transmembrane proteins* Correspondence: l.kenny@imperial.ac.uk
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in any medium, provided the original work is pessential for maintaining the relationship between the cell
and the extracellular matrix and that have been found to
be upregulated on tumor vascular neoendothelium [4,5].
[18F]fluciclatide is an arginine-glycine-aspartic acid
(RGD) peptide which binds the αvβ3 and αvβ5 integ-
rins with high affinity [6]. We have previously studied
the dosimetry and biodistribution of this compound la-
belled with F-18 in healthy volunteers with positron
emission tomography (PET) [7] and the uptake profile
of the tracer in patients with metastatic breast cancer
[8]. The latter study showed significantly higher radio-
tracer uptake in lung metastases from breast cancer
compared to normal lung tissue. [18F]galacto-RGD is a
similar promising agent for studying integrin-related
angiogenesis developed by Wester's group [9], and sub-
sequently studied by Beer et al. who demonstrated that
there is high uptake of this compound in a variety ofn Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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relates with expression of the αvβ3 integrin measured
using immunohistochemistry [11].
The purpose of this study was to understand the rela-
tionship between perfusion assessed by [15O]H2O and
18F-fluciclatide kinetics in non-small cell lung cancer
(NSCLC) and melanoma, where Phase 1 trials of hu-
manized antibodies and peptides targeted to integrins
have shown promise [12,13]. These two tumor types
have also been shown to have varying degrees of αvβ3
and αvβ5 expression on tumor cells relative to vascular
endothelium with melanoma suggested to have expression
on both tumor and vascular endothelium and NSCLC
suggested to have expression predominantly on the vascu-
lar endothelium [4]. The underlying hypothesis for the
study was that fluciclatide retention in tumors is initially
dependent on perfursion, but at later timepoints, retention
is independent of perfusion.
Methods
Patients were recruited from oncology clinics at the
Imperial College NHS Healthcare trust and the Royal
Marsden Hospital NHS Trust. The study was approved
by the hospital Local Research Ethics Committee in ac-
cordance with the Helsinki Declaration revised guide-
lines (2008). The eligibility criteria were as follows:
patients aged ≤80 years old with a histological proven
NSCLC or melanoma, and one site of measureable disease
of ≥2-cm diameter, with a treatment-free interval of 3 weeks
(or 4 weeks for radiotherapy to the imaging site), life expect-
ancy of at least 3 months, haemoglobin ≤10 g/dL, gran-
ulocyte count of ≥1.5 × 109, platelet count of ≥100 × 109,
adequate hepatic function; exclusion criteria: pregnant
or lactating patients, sexually active patients who are not
employing adequate contraception. Additional details are
provided in Table 1.
Radiosynthesis of 18F-fluciclactide and PET
scanning procedure
The chemical synthesis of the precursor of fluciclatide has
previously been described [6], radiolabelling was performed
at Hammersmith Imanet as previously described on anTable 1 Demographics of the patients studied
Patient Age Diagnosis Stage Dynamic imaging region
1 81 Melanoma IV Thorax
2 62 NSCLC* IIIA Thorax
3 57 NSCLC IIIB Thorax/Neck
4 59 NSCLC IB Thorax
5 66 NSCLC IV Thorax
6 79 Melanoma IV Knee
7 59 NSCLC IV Thorax
NSCLC, non-small cell lung cancer.automated module (TRACERlab FX F-N; GE Healthcare).
The specific activity and radiochemical purity of the injec-
tate, determined by high-performance liquid chromatog-
raphy (HPLC), was 320 GBq/μmol and 99.7 %, respectively.
All patients were scanned on a PET-CT (GE-Discovery
RX) scanner after being positioned such that the field of
view (FOV) included the tumor volume of interest. The
axial FOV of the scanner was 15.7 cm and the transaxial
FOV was 70 cm. A low-dose CT scan (20 mA and 120 kV)
was used for attenuation correction prior to the PET scan.
A target dose of 600 MBq [15O]H2O was injected i.v. over
20 s followed by a 30-s flush with normal saline. Dynamic
PET scanning was done for 8 min and 40 s with the follow-
ing frame durations: 30 s × 1, 20 s × 1, 5 s × 22, 10 s × 3,
30 s × 5, and 60 s × 3. After a 2-min break to allow for radio-
active decay (15O half-life = 2.04 min), the [18F]fluciclatide
scan was performed. [18F]fluciclatide was administered by
a bolus i.v. injection over 10 to 30 s. The PET acquisition
was conducted as a single bed position dynamic scan
(three-dimensional acquisition) centred on the tumor
volume of interest (VOI) for 66.5 min. Data were binned
into the following time frames: 10 s × 10, 20 s × 4, 30 s × 4,
60 s × 7, 120 s × 4, 300 s × 3, and 600 s × 3. Sinograms
were Fourier-rebinned into two-dimensional slices and re-
constructed (with correction for attenuation, scatter, and
dead time) using filtered back-projection (ramp filter ker-
nel full-width-at-half-maximum of 2.0 mm). The final im-
ages had 128 × 128 × 47 voxels of 2.62 × 2.62 × 2.42 mm3.
In order to derive an input function, blood samples
were taken during the [15O]H2O scan via a radial artery
cannula continuously at a rate of 5 mL/min for the first
9 min 40 s; discrete samples were taken at 3, 6, and 8 min
40 s. Similarly, continuous arterial sampling (5 mL/min)
was performed for 10 min during the [18F]fluciclatide
scan; seven discrete samples (5 to 10 mL) were taken at
2.5, 5, 10, 15, 30, 45, 60 min. Metabolite analyses were per-
formed on the 2.5-, 5-, 10-, 30-, and 60-min samples. The
computation of [18F]fluciclatide parent fraction and input
function was carried out as described in [7].
Data analysis
Volumes-of-interest (VOIs) were manually defined around
visible tumors from the [18F]fluciclatide summed images
using the Analyze software (Version 7). The same VOIs
were applied to the [15O]H2O scan to extract tumor
time-activity curves (TACs) for both tracers.
To estimate the perfusion from the [15O]H2O data, a
one-tissue compartment model was employed:
CT tð Þ ¼ 1−V bð Þ  ½K1  ½Ca tð Þ⊗ exp −k2  tð Þ þ V bCa tð Þ
ð1Þ
In Equation 1, CT(t) indicates the tumor TAC, Ca(t)
the measured radioactivity concentration in arterial
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3/min), k2
(1/min) the transfer rate from tissue to blood,Vb (unitless)
the blood volume fraction and ⊗ the convolution operator.
K1, k2, and Vb were estimated for each VOI by fitting CT(t)
to Equation 1 using the standard weighted non-linear
least squares (WNLLS). WNLLS minimizes the weighted
residual sum of squares (WRSS)
WRSS pð Þ ¼
Xn




with p, ti, and n indicating respectively the parameter
vector [K1;k2;Vb], the mid-time of the ith frame, and the
number of frames. In Equation 2 weights wi were set to
wi ¼ ΔiC tið Þ exp λtið Þ ð3Þ
Tomasi G 2009, [14] with Δi and λ indicating respectively
the duration of the ith frame and the half-life of 15O. The
delay between Ca(t) and CT(t) was modelled by shifting
CT(t) of i seconds (i = 0,1, …, 30) and then retaining the
value of the delay which gave rise to the smallest WRSS.
A two-tissue reversible compartment model was used
to model [18F]fluciclatide kinetics, consistent with our
previous study [8]. The metabolite-corrected measured
arterial concentration of [18F]fluciclatide was used as in-
put function for estimating with WNNLS the parameters
K1 (mL/cm
3/min), k2 (1/min), k3 (1/min), k4 (1/min), Vb
(unitless) for each VOI. Weights were computed from
Equation 3. The parameter k3/k4 ratio - a measure of the
binding potential - was then computed for each VOI; as
we previously reported [8], this parameter was the best of
a number of parameters examined to differentiate between
healthy and tumor VOIs.
K1, k2, and Vb were also estimated at the voxel level
for [15O]H2O using the standard Basis Function Method
approach [15]. The final maps, however, were extremely
noisy because of the high noise of [15O]H2O data and
we did not include them in the analysis. Parametric
maps were not generated in the case of [18F]fluciclatide
because of the difficulty of fitting a five-parameter model
at the voxel level. To analyze the correlation between
perfusion and [18F]fluciclatide uptake at the voxel level
we employed the following semi-quantitative parameters.
For [15O]H2O we used
SUVwater m
2=L





In Equation 4, we arbitrarily chose 1.5 min as the final
time, instead of the scan duration of 8 min, to define a
parameter describing [15O]H2O delivery (i.e. flow) beforewashout took place. To measure [18F]fluciclatide retention,
we employed
SUV fluci RETENTION m
2=L
  ¼ CT tið ÞInjected dose
BSA
ð5Þ
In Equations 4 and 5, BSA denotes the body surface area,
and ti in Equation 5 indicates the mid-time of the last frame
of the [18F]fluciclatide scan (60.5 min). We also defined a
parameter describing [18F]fluciclatide delivery as
SUV fluci DELIVERY m
2=L





where the same upper limit used for SUVwater was
employed. These parameters were computed for each voxel
of the tumor VOIs and the agreement of SUVwater with
SUVfluci RETENTION and SUVfluci DELIVERY was
assessed using Spearman's correlation coefficient.
Results
The activity of injected [18F]fluciclatide ranged between
290 and 383 MBq, and that of [15O]H2O between 448
and 697 MBq. Due to tracer failure and patient comfort
reasons, PET scans of both tracers were carried out in
four patients; for two patients, only the [18F]fluciclatide
data were obtained, and for the remaining patient, only
the [15O]H2O data were obtained.
Typical images of [15O]H2O and [
18F]fluciclatide are
shown in Figure 1A,B, respectively. The quality of the
fits was good for both tracers. Examples are displayed in
Figure 2A for [15O]H2O and Figure 2B for [
18F]fluciclatide.
In Table 2, the kinetic parameters for [15O]H2O and the
k3/k4 ratios of [
18F]fluciclatide at the VOI level are re-
ported. For completeness, we also reported SUV parame-
ters for [18F]fluciclatide.
The k3/k4 ratio of [
18F]fluciclatide was 5.39 ± 1.46, in
good agreement with our previous results in lung metas-
tases (k3/k4 = 6.09 ± 3.04). There was a good correlation
(Pearson r = 0.71, p value = 0.06, Figure 3) between
SUVfluci RETENTION (x-axis) and k3/k4 (y-axis) at the
VOI level supporting the use of the semi-quantitative par-
ameter SUVfluci RETENTION as a measure of retention.
To investigate the relationship between perfusion and
[18F]fluciclatide retention, which was not feasible at the
VOI level due to the low number of subjects completing
both scans, we compared SUVwater with SUVfluci
RETENTION or SUVfluci DELIVERY at the voxel level.
As expected, SUVwater was well correlated with SUVfluci
DELIVERY, the correlation being statistically significant for
voxels within all four tumors (p value <10−4 for all VOIs).
The correlation between SUVwater and SUVfluci
RETENTION, on the other hand, was not statistically
Figure 1 Summed images of (A) [15O]H2O and (B) [
18F]fluciclatide.
These were in a patient with non-small cell lung cancer with bilateral
cervical lymph node metastases. The blood vessels are labelled.
Figure 2 Time-activity curves for (A) [15O]H2O and
(B) [18F]fluciclatide.
Table 2 Kinetic parameters for [15O]H2O and [
18F]fluciclatide
















(mL/cm3/min) (L/min) (unitless) (m2/L) (m2/L)
1 0.15 0.32 4.34 0.070 0.049
2 0.16 0.38 4.37 0.137 0.072
3 0.38 0.61 4.87 0.045 0.064
4 N/A N/A 7.81 0.050 0.087
5 N/A N/A 6.57 0.040 0.070
6 0.68 0.88 N/A N/A N/A
(Tumor#1)
6 0.39 0.62 N/A N/A N/A
(Tumor#2)
7 0.44 0.72 4.38 0.077 0.062
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This information is displayed in Figure 4, which shows the
relationship between SUVwater (x-axis) and SUVfluci
DELIVERY (y-axis, Figure 4A,C,E,G for patients 1, 2, 3,
and 7, respectively) and between SUVwater and SUVfluci
RETENTION (y-axis, Figure 4B,D,F,H). The plots on the
same row correspond to the same patients and the continu-
ous line is the fitted line of equation y =mx + q. Whereas a
monotonic relationship can be noticed between SUVwater
and SUVfluci DELIVERY, there is no clear visual relation-
ship between SUVwater and SUVfluci RETENTION .
Discussion
There is an increasing need for effective biomarkers which
can reliably predict the response to novel therapeutics act-
ing as angiogenesis inhibitors or as vascular disruptingFigure 3 Correlation between [18F]fluciclatide retention SUV
and k3/k4 ratio.
Figure 4 Relationship between fluciclatide delivery and water SUV (A,C,E,G) and between SUV fluciclatide retention and SUV for water
(B,D,F,H). There was a lack of relationship between between SUV fluciclatide retention and SUV for water.
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is very promising in this respect. Given the haemodynamic
context of angiogenesis, the uptake characteristics of a
good biomarker should be independent of blood flow.
Consequently, the objective of this study, which is of
scientific relevance to the use of this and possibly other
RGD-based ligands, was to assess the dependency of
[18F]fluciclatide uptake on perfusion. The major finding
of the study is that, at the voxel level, [18F]fluciclatide
retention is not correlated with perfusion measured by
[15O]H2O uptake. We contrast this finding with a good
agreement, as expected, between [15O]H2O uptake and
[18F]fluciclatide delivery suggesting that the lack of correl-
ation between [15O]H2O uptake and [
18F]fluciclatide reten-
tion was not due to noise. Incidentally, the two-tissue
compartment model which we validated for [18F]fluciclatide
in our previous report proved to be appropriate also for this
dataset, and the mean k3/k4 ratio obtained in this study(5.39 ± 1.46) was in good agreement with the results
obtained in lung metastases (k3/k4 = 6.09 ± 3.04).
The main limit in this initial study is the small sam-
ple size, as only four out of seven patients successfully
completed both scans, which hampered the quantifica-
tion of the relationship between K1 of [
15O]H2O and
[18F]fluciclatide k3/k4 at the VOI level. In this regard
our future plan is to test further these preliminary
findings on a larger cohort of subjects and also to
apply/develop appropriate noise-reduction approaches
which will allow us to compare K1 maps of [
15O]H2O
and k3/k4 of [
18F]fluciclatide at the voxel level.
Conclusion
In conclusion, these preliminary results support the
view that [18F]fluciclatide binding (retention) is not
dependent on perfusion, highlighting the potential of
this radiotracer in the study of receptors expressed on the
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aging protocols (60 min post injection) for assessment
of [18F]fluciclatide uptake.
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